Clinical Trial

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-03.
Trial Details
NCT Number NCT06764017
Lead Sponsor First Affiliated Hospital of Ningbo University
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 30 participants
Start Date 2025-02-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-19